Alastair D Hay1, Paul Little2, Anthony Harnden3, Matthew Thompson4, Kay Wang3, Denise Kendrick5, Elizabeth Orton5, Sara T Brookes6, Grace J Young7, Margaret May6, Sandra Hollinghurst1, Fran E Carroll8, Harriet Downing1, David Timmins3, Natasher Lafond5, Magdy El-Gohary2, Michael Moore2. 1. Centre for Academic Primary Care, National Institute for Health Research (NIHR) School for Primary Care Research, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England. 2. Primary Care and Population Science, NIHR School for Primary Care Research, Faculty of Medicine, University of Southampton, Aldermoor Health Center, Southampton, England. 3. Nuffield Department of Primary Care Health Sciences, NIHR School for Primary Care Research, University of Oxford, Oxford, England. 4. Department of Family Medicine, University of Washington, Seattle. 5. Division of Primary Care, NIHR School for Primary Care Research, School of Medicine, University of Nottingham, Nottingham, England. 6. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England. 7. Bristol Randomised Trials Collaboration, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England. 8. Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
Abstract
Importance: Acute lower respiratory tract infection is common and often treated inappropriately in primary care with antibiotics. Corticosteroids are increasingly used but without sufficient evidence. Objective: To assess the effects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma. Design, Setting, and Participants: Multicenter, placebo-controlled, randomized trial (July 2013 to final follow-up October 2014) conducted in 54 family practices in England among 401 adults with acute cough and at least 1 lower respiratory tract symptom not requiring immediate antibiotic treatment and with no history of chronic pulmonary disease or use of asthma medication in the past 5 years. Interventions: Two 20-mg prednisolone tablets (n = 199) or matched placebo (n = 202) once daily for 5 days. Main Outcomes and Measures: The primary outcomes were duration of moderately bad or worse cough (0 to 28 days; minimal clinically important difference, 3.79 days) and mean severity of symptoms on days 2 to 4 (scored from 0 [not affected] to 6 [as bad as it could be]; minimal clinically important difference, 1.66 units). Secondary outcomes were duration and severity of acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic use, and adverse events. Results: Among 401 randomized patients, 2 withdrew immediately after randomization, and 1 duplicate patient was identified. Among the 398 patients with baseline data (mean age, 47 [SD, 16.0] years; 63% women; 17% smokers; 77% phlegm; 70% shortness of breath; 47% wheezing; 46% chest pain; 42% abnormal peak flow), 334 (84%) provided cough duration and 369 (93%) symptom severity data. Median cough duration was 5 days (interquartile range [IQR], 3-8 days) in the prednisolone group and 5 days (IQR, 3-10 days) in the placebo group (adjusted hazard ratio, 1.11; 95% CI, 0.89-1.39; P = .36 at an α = .05). Mean symptom severity was 1.99 points in the prednisolone group and 2.16 points in the placebo group (adjusted difference, -0.20; 95% CI, -0.40 to 0.00; P = .05 at an α = .001). No significant treatment effects were observed for duration or severity of other acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic use, or nonserious adverse events. There were no serious adverse events. Conclusions and Relevance: Oral corticosteroids should not be used for acute lower respiratory tract infection symptoms in adults without asthma because they do not reduce symptom duration or severity. Trial Registration: ISRCTN.com Identifier: ISRCTN57309858.
Importance: Acute lower respiratory tract infection is common and often treated inappropriately in primary care with antibiotics. Corticosteroids are increasingly used but without sufficient evidence. Objective: To assess the effects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma. Design, Setting, and Participants: Multicenter, placebo-controlled, randomized trial (July 2013 to final follow-up October 2014) conducted in 54 family practices in England among 401 adults with acute cough and at least 1 lower respiratory tract symptom not requiring immediate antibiotic treatment and with no history of chronic pulmonary disease or use of asthma medication in the past 5 years. Interventions: Two 20-mg prednisolone tablets (n = 199) or matched placebo (n = 202) once daily for 5 days. Main Outcomes and Measures: The primary outcomes were duration of moderately bad or worse cough (0 to 28 days; minimal clinically important difference, 3.79 days) and mean severity of symptoms on days 2 to 4 (scored from 0 [not affected] to 6 [as bad as it could be]; minimal clinically important difference, 1.66 units). Secondary outcomes were duration and severity of acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic use, and adverse events. Results: Among 401 randomized patients, 2 withdrew immediately after randomization, and 1 duplicate patient was identified. Among the 398 patients with baseline data (mean age, 47 [SD, 16.0] years; 63% women; 17% smokers; 77% phlegm; 70% shortness of breath; 47% wheezing; 46% chest pain; 42% abnormal peak flow), 334 (84%) provided cough duration and 369 (93%) symptom severity data. Median cough duration was 5 days (interquartile range [IQR], 3-8 days) in the prednisolone group and 5 days (IQR, 3-10 days) in the placebo group (adjusted hazard ratio, 1.11; 95% CI, 0.89-1.39; P = .36 at an α = .05). Mean symptom severity was 1.99 points in the prednisolone group and 2.16 points in the placebo group (adjusted difference, -0.20; 95% CI, -0.40 to 0.00; P = .05 at an α = .001). No significant treatment effects were observed for duration or severity of other acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic use, or nonserious adverse events. There were no serious adverse events. Conclusions and Relevance: Oral corticosteroids should not be used for acute lower respiratory tract infection symptoms in adults without asthma because they do not reduce symptom duration or severity. Trial Registration: ISRCTN.com Identifier: ISRCTN57309858.
Authors: Paul Little; Kate Rumsby; Joanne Kelly; Louise Watson; Michael Moore; Gregory Warner; Tom Fahey; Ian Williamson Journal: JAMA Date: 2005-06-22 Impact factor: 56.272
Authors: Reed A C Siemieniuk; Maureen O Meade; Pablo Alonso-Coello; Matthias Briel; Nathan Evaniew; Manya Prasad; Paul E Alexander; Yutong Fei; Per O Vandvik; Mark Loeb; Gordon H Guyatt Journal: Ann Intern Med Date: 2015-10-06 Impact factor: 25.391
Authors: Katherine E Fleming-Dutra; Adam L Hersh; Daniel J Shapiro; Monina Bartoces; Eva A Enns; Thomas M File; Jonathan A Finkelstein; Jeffrey S Gerber; David Y Hyun; Jeffrey A Linder; Ruth Lynfield; David J Margolis; Larissa S May; Daniel Merenstein; Joshua P Metlay; Jason G Newland; Jay F Piccirillo; Rebecca M Roberts; Guillermo V Sanchez; Katie J Suda; Ann Thomas; Teri Moser Woo; Rachel M Zetts; Lauri A Hicks Journal: JAMA Date: 2016-05-03 Impact factor: 56.272
Authors: Evan L Dvorin; Marie Claire Lamb; Dominique J Monlezun; Austin C Boese; Lydia A Bazzano; Eboni G Price-Haywood Journal: JAMA Intern Med Date: 2018-06-01 Impact factor: 21.873
Authors: Koen B Pouwels; F Christiaan K Dolk; David R M Smith; Timo Smieszek; Julie V Robotham Journal: J Antimicrob Chemother Date: 2018-02-01 Impact factor: 5.790
Authors: Akhilesh Jha; Jake Dunning; Tanushree Tunstall; Ryan S Thwaites; Long T Hoang; Onn Min Kon; Maria C Zambon; Trevor T Hansel; Peter J Openshaw Journal: Eur Respir J Date: 2019-10-24 Impact factor: 33.795
Authors: Aida Moure-Fernandez; Sandra Hollinghurst; Fran E Carroll; Harriet Downing; Grace Young; Sara Brookes; Margaret May; Magdy El-Gohary; Anthony Harnden; Denise Kendrick; Natasher Lafond; Paul Little; Michael Moore; Elizabeth Orton; Matthew Thompson; David Timmins; Kay Wang; Alastair D Hay Journal: BMJ Open Date: 2020-02-18 Impact factor: 2.692
Authors: Christoph Merlo; Stefan Essig; D Oana Brancati-Badarau; Jörg Daniel Leuppi; Benjamin Speich; Tobias E Erlanger; Lars G Hemkens; Andreas Zeller Journal: Trials Date: 2020-11-23 Impact factor: 2.279
Authors: Amy Whitehead; Catherine Simpson; Merlin Willcox; Frances Webley; Alastair D Hay; Chris Butler; Lily Yao; Emma Wrixon; Margaret Bell; Jennifer Bostock; Paul Little; Gareth Griffiths; Michael Moore Journal: Pilot Feasibility Stud Date: 2019-07-31